(Date:11/20/2009)...TOLEDO recently announced that Dr. Dominique Hebra...f Process Analytical Technology (PAT) in Green Che... 2009. , (PRWEB) November...tical Technology (PAT) in Green Chemistry and Gree...ytical Technology (PAT) case studies will be prese...
(Date:11/19/2009)...swire-FirstCall/ -- Omeros Corporation (Nasdaq: O...for the third quarter ended September 30, 2009. Fo...s reported a net loss of $3.9 million, or $1.34 pe..., or $2.54 per share, for the same period in 2008.... Company reported a net loss of $15.5 million, or ...
(Date:11/19/2009)...wswire-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NB...g letter to its shareholders, discussing the Compa...opharmaceuticals Holdings, Inc. (CHBP), an integra...,s Republic of China. The merger gives NeoStem a c...cal Co. Ltd., CHBP,s primary operating subsidiary ...
(Date:11/19/2009)..., November 19 MONITORING FORCE Gmb... 2009 Flibanserin in the,indication treatment-rele...sease for orphan drug status designation with the ... dyskinesia is a complication of the mainstay,trea... to some of those,affected, since it may be disabl...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2...te Placement of Convertible Preferred Stock -, DA...ulletin Board: ACCP) announced today that it has e... The Company has entered into agreements,with inst...aggregate of,$2.7 million in gross proceeds of the...his equity is in addition to the $9.5 million in g...
...ity data on lead NNRTI, RDEA806, and next generati...scussed -, CARLSBAD, Calif., Jan. 29 Ardea Biosc...preclinical data on the Company,s,non-nucleoside r...ompounds,including RDEA806, RDEA427 and RDEA640, w... on Retroviruses and Opportunistic Infections (CRO...
... Calif., Jan. 29 Edwards Lifesciences,Corporation...heart valves,today announced that it has received ...dministration (FDA) for a revised design to the U....anscatheter aortic heart valve,technology. The FDA...,delivery system to the trial, and also granted pe...
Other Biology Technology:Access Pharmaceuticals Announces $2.7 Million New Equity 2Access Pharmaceuticals Announces $2.7 Million New Equity 3Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 2Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections 3Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 2Edwards Lifesciences Receives FDA Approval to Add Transapical Delivery System to U.S. Clinical Trial of Transcatheter Heart Valve 3Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation
...ging system for detection of very low level of lum... extreme sensitive camera to detect low level ligh...us disease research, gene expression, circadian rh... with a motor-driven camera inside the light-tight...
... sets a new standard for high performance flow cyt...strumentation, this easy-to-use benchtop system de... The BD FACSAria instrument is the first benchtop ... flow cell. This new flow cell provides superior ...
Mouse Anti-Human IFNA13 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: